Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | BLK | P51451 | 15/20 | 0.84 |
| ▸ | BTK | Q06187 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680905 | 0.91 | EGFR (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16681185 | 0.90 | FLT3 (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16680536 | 0.88 | FLT3 (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16681336 | 0.88 | FLT3 (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16680981 | 0.86 | FLT3 (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16680260 | 0.85 | FLT3 (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16680898 | 0.82 | FLT3 (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16681301 | 0.82 | EGFR (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16680409 | 0.80 | FLT3 (1.00) | FLT3EGFRBLKBTK | |
| SCHEMBL16681075 | 0.79 | FLT3 (1.00) | FLT3EGFRBLKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670213-B2 | Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-06-06 | — | — | US | disclosed |
| US-9670213-B2 | Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-06-06 | — | — | US | disclosed |
| CN-106008511-A | Pteridinone derivatives and application of pteridinone derivatives as EGFR (epidermal growth factor receptor tyrosine kinase), BLK (B lymphocyte tyrosine kinase) and FLT3 (FMS-like tyrosine kinase 3) inhibitors | 华东理工大学 | 2016-10-12 | — | — | CN | disclosed |
| CN-103930425-B | Pteridinone derivatives and their use as EGFR, BLK, FLT3 inhibitors | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-04-27 | — | — | CN | disclosed |
| US-20150126508-A1 | PTERIDINE KETONE DERIVATIVE AND APPLICATIONS THEREOF AS EGFR, BLK, AND FLT3 INHIBITOR | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. (CN) | 2015-05-07 | — | — | US | disclosed |
| US-20150126508-A1 | PTERIDINE KETONE DERIVATIVE AND APPLICATIONS THEREOF AS EGFR, BLK, AND FLT3 INHIBITOR | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. (CN) | 2015-05-07 | — | — | US | disclosed |
| CN-103833759-A | Pteridinone derivatives as BLK and FLT3 inhibitors and applications thereof | UNIV EAST CHINA SCIENCE & TECH | 2014-06-04 | — | — | CN | disclosed |
| CN-103421010-A | Pteridinone derivative as EGFR inhibitor and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2013-12-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126508-A1 | PTERIDINE KETONE DERIVATIVE AND APPLICATIONS THEREOF AS EGFR, BLK, AND FLT3 INHIBITOR | FLT3, BLK, EGFR | FLT3 1/4885EGFR 3/4885BLK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.